1,408
Views
7
CrossRef citations to date
0
Altmetric
Research Paper

Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly

An observational study in Liguria Region, Italy

, , , , , , , , , , , , , , , , , , , & show all
Pages 172-177 | Received 18 Jul 2014, Accepted 26 Jul 2014, Published online: 01 Nov 2014

References

  • Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816 - 9; PMID: 23051612
  • Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67:71 - 9; http://dx.doi.org/10.1136/thx.2009.129502; PMID: 20729232
  • Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, Schraeder P, Welte T, Hoeffken G. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax 2009; 64:1062 - 9; http://dx.doi.org/10.1136/thx.2008.109785; PMID: 19454409
  • Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008; 47:1328 - 38; http://dx.doi.org/10.1086/592691; PMID: 18844484
  • Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010; 28:4955 - 60; http://dx.doi.org/10.1016/j.vaccine.2010.05.030; PMID: 20576535
  • Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Clin Microbiol Infect 2013; 19:Suppl 1 1 - 9; http://dx.doi.org/10.1111/1469-0691.12320; PMID: 24083785
  • Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011; 10:1143 - 67; http://dx.doi.org/10.1586/erv.11.99; PMID: 21810065
  • Alicino C, Barberis I, Orsi A, Durando P. Pneumococcal vaccination strategies in adult population: perspectives with the pneumococcal 13 - valent polysaccharide conjugate vaccine. Minerva Med 2014; 105:89 - 97; PMID: 24572454
  • Raymond F, Boucher N, Allary R, Robitaille L, Lefebvre B, Tremblay C, Corbeil J, Gervaix A. Serotyping of Streptococcus pneumoniae based on capsular genes polymorphisms. PLoS One 2013; 8:e76197; http://dx.doi.org/10.1371/journal.pone.0076197; PMID: 24086706
  • Centers for Disease Control and Prevention (CDC). Progress in introduction of pneumococcal conjugate vaccine - worldwide, 2000-2012. MMWR Morb Mortal Wkly Rep 2013; 62:308 - 11; PMID: 23615674
  • Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; 1:CD000422; PMID: 18253977
  • Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422; PMID: 23440780
  • Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; 11:CD001390; PMID: 21069668
  • European Medicines Agency. 22 September 2011 EMA/CHMP/763049/2011 Committee for Medicinal Products for Human Use (CHMP) Available from http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/
  • Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep 2012; 61:394 - 5; PMID: 22647745
  • Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31:3585 - 93; http://dx.doi.org/10.1016/j.vaccine.2013.05.010; PMID: 23688527
  • Schwarz TF, Flamaing J, Rümke HC, Penzes J, Juergens C, Wenz A, Jayawardene D, Giardina P, Emini EA, Gruber WC, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 2011; 29:5195 - 202; http://dx.doi.org/10.1016/j.vaccine.2011.05.031; PMID: 21619909
  • Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 2014; 32:2364 - 74; http://dx.doi.org/10.1016/j.vaccine.2014.02.002; PMID: 24606865
  • Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012; 205:1408 - 16; http://dx.doi.org/10.1093/infdis/jis212; PMID: 22457293
  • Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012; 31:501 - 8; http://dx.doi.org/10.1097/INF.0b013e31824de9f6; PMID: 22327872
  • Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CGUS. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155 - 63; http://dx.doi.org/10.1056/NEJMoa1209165; PMID: 23841730
  • Ansaldi F, de Florentiis D, Canepa P, Ceravolo A, Rappazzo E, Iudici R, Martini M, Botti G, Orsi A, Icardi G, et al. Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation. Hum Vaccin Immunother 2013; 9:614 - 20; http://dx.doi.org/10.4161/hv.23253; PMID: 23292052
  • Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378 - 83; PMID: 18990781
  • Bonten M, Bolkenbaas M, Huijts S, Webber C, Gault S, Gruber W, et al. Community acquired pneumonia immunisation trial in adults (CAPITA), ISPPD-9/pneumonia 2014 Mar 9-13;3:1-286.
  • Deliberation of the Regional Council 19/07/2013 n. 891 Regional Plan preventable by vaccination. Official Bulletin of the Region of Liguria Prevention of pneumococcal disease in adults older than 64 years and in young people and adults with factors risk-operative instructions. prot. n. PG/2013
  • European Medicine Agency. Prevenar. Summary of product characteristics. Available from http://www.ema.europa.eu/docs/it_IT/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf
  • Durando P, Alicino C, Alberti M, Sticchi L, Turello V, Marensi L, Caiazzo AL, Panico MG, Giugliano F, Parlato A, et al, Italian Intradermal Influenza Vaccine Working Group. Acceptance and safety of the intradermal influenza vaccine among the elderly in Italy: an on-field national study. Adv Ther 2012; 29:312 - 26; http://dx.doi.org/10.1007/s12325-012-0012-1; PMID: 22529024

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.